Alector, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Alector, Inc. ("Alector" or the "Company") (ALEC). Impacted investors are advised to contact the firm now.

Alector is a biotechnology company developing therapies for neurodegenerative diseases, including frontotemporal dementia and Alzheimer’s. Its lead candidate, latozinemab (AL001), targets progranulin deficiencies linked to these conditions.

The law firm is investigating whether Alector and certain of its officers and directors may have engaged in securities fraud or other unlawful business practices from October 2023 through October 2025. During this time, Alector made positive statements about the Phase 3 INFRONT-3 trial, emphasizing that the study remained on track and citing the drug’s FDA designations such as Orphan Drug, Breakthrough Therapy and Fast Track. Attorneys will examine whether the Company failed to disclose key risks, including uncertainty that elevated biomarker levels would lead to meaningful clinical improvement in patients with frontotemporal dementia.

On October 21, 2025, after market close, Alector announced that the Phase 3 trial of latozinemab failed to meet its co-primary endpoint and showed no effect on disease progression. The Company also disclosed the discontinuation of related studies, a significant workforce reduction, and the resignation of its head of research and development.

Following the disclosure, Alector’s shares declined nearly 50%, sliding from $3.21 on October 21 to $1.58 on October 22, 2025.

If you purchased Alector (NASDAQ: ALEC) securities between October 2023 and October 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.